Stockscreener 앱 받기
17.79
3.99%
-0.78
전일 마감가:
$18.57
열려 있는:
$18.58
하루 거래량:
259.75K
Relative Volume:
0.19
시가총액:
$1.94B
수익:
$525.66M
순이익/손실:
$-192.74M
주가수익비율:
-9.5645
EPS:
-1.86
순현금흐름:
$-120.97M
1주 성능:
+7.34%
1개월 성능:
-0.40%
6개월 성능:
+27.53%
1년 성능:
-7.62%
1일 변동 폭
$17.63
$18.75
1주일 범위:
$16.26
$18.75
52주 변동 폭
$10.87
$24.73
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Taking on analysts’ expectations and winning: NovoCure Ltd (NVCR) - SETE News
Chief Financial Officer Cordova Ashley sold 688 shares of NovoCure Ltd [NVCR] - Knox Daily
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects - Simply Wall St
NovoCure Ltd (NVCR) expanding its growth trajectory ahead - SETE News
Alternating Electric Field Tumor Treatment Market Business - openPR
Financial Health Check: Examining NovoCure Ltd (NVCR)’s Key Ratios - The Dwinnex
NovoCure Ltd (NVCR)’s stock chart: A technical perspective - US Post News
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy - StockTitan
NovoCure Ltd [NASDAQ: NVCR] Sees Increase in Stock Value - Knox Daily
Why NovoCure Stock Dived by 13% This Week - The Motley Fool
NovoCure (NASDAQ:NVCR) Shares Down 5.5% - MarketBeat
NovoCure (NASDAQ:NVCR) Stock Price Up 13.7% - MarketBeat
Stock Surge: NovoCure Ltd (NVCR) Closes at 16.70, Marking a -0.30 Increase/Decrease - The Dwinnex
NVCR November 15th Options Begin Trading - Nasdaq
The Psychology of NovoCure Ltd Inc. (NVCR) Price Performance: Understanding Market Sentiment - The InvestChronicle
NovoCure (NASDAQ:NVCR) Shares Gap Down to $19.44 - MarketBeat
Novocure announces leadership transition, CEO to retire By Investing.com - Investing.com Canada
Novocure falls as CEO Asaf Danziger to step down - XM
There is no way NovoCure Ltd (NVCR) can keep these numbers up - SETE News
Novocure announces leadership transition, CEO to retire - Investing.com
Novocure announces planned CEO transition, COO to step down - TipRanks
Novocure Announces Planned CEO Transition - Financial Times
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Perhaps timely catching NovoCure Ltd (NVCR) would be a good idea - SETE News
Gaining Ground: NovoCure Ltd (NVCR) Closes Higher at 19.75, Up 0.10 - The Dwinnex
NovoCure Ltd (NVCR) Stock: A Year of Decreases and Increases - The InvestChronicle
NVCR’s latest rating updates from top analysts. - Knox Daily
NovoCure (NASDAQ:NVCR) Trading Up 2.8% - MarketBeat
What technical indicators reveal about NVCR stock - US Post News
Novocure to Participate in 2024 Wells Fargo Healthcare Conference - Yahoo Finance
Anaplastic Astrocytoma Market Report Details Trends, and Future Opportunities - WhaTech
AngioDynamics (NASDAQ:ANGO) and NovoCure (NASDAQ:NVCR) Head to Head Review - Defense World
Baillie Gifford & Co. Has $28.91 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Insider Selling: Cordova Ashley, NovoCure Ltd [NVCR] Chief Financial Officer divested 688 shares - Knox Daily
A better buy-in window may exist right now for NovoCure Ltd (NVCR) - SETE News
NovoCure Ltd (NVCR) stock analysis: A simple moving average approach - US Post News
Market Watch: NovoCure Ltd (NVCR)’s Noteworthy Drop, Closing at 17.90 - The Dwinnex
NovoCure (MEX:NVCR) Graham Number : MXNN/A (As of Jun. 2024) - GuruFocus.com
NovoCure (NASDAQ:NVCR) Stock Price Down 3.2% - MarketBeat
NVCR’s 52-Week Rollercoaster: From $10.87 to $31.73 – What’s Next for Investors? - The InvestChronicle
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet - Yahoo Finance
NVCR (NovoCure) 14-Day RSI : 48.34 (As of Aug. 16, 2024) - GuruFocus.com
NovoCure (NASDAQ:NVCR) Trading Up 9.4% - MarketBeat
NVCR (NovoCure) 9-Day RSI : 31.29 (As of Aug. 15, 2024) - GuruFocus.com
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer - Yahoo Finance
Metric Deep Dive: Understanding NovoCure Ltd (NVCR) Through its Ratios - The Dwinnex
NovoCure Ltd (NVCR)’s stock performance: a year in review - US Post News
Is Spruce Biosciences Inc (NASDAQ: SPRB) A Good Investment Now? - Stocks Register
Metrics That Matter About Ionis Pharmaceuticals Inc (NASDAQ: IONS) - Stocks Register
Things To Consider Before Buying CBRE Group Inc (NYSE: CBRE) - Stocks Register
The Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Stock Price: Is It Overvalued? - Stocks Register
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Jun 05 '24 |
Option Exercise |
22.82 |
124,373 |
2,838,192 |
124,373 |
| VERNON W ANTHONY | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,033 |
164,833 |
| Scannell Timothy J | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,027 |
2,964 |
| LEUNG GABRIEL | Director |
Jun 04 '24 |
Sale |
23.89 |
964 |
23,025 |
78,175 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 01 '24 |
Sale |
16.03 |
2,107 |
33,769 |
252,452 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Mar 04 '24 |
Sale |
16.01 |
1,217 |
19,484 |
251,235 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Mar 01 '24 |
Sale |
16.03 |
1,679 |
26,909 |
160,938 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Mar 04 '24 |
Sale |
16.01 |
840 |
13,448 |
160,098 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Feb 28 '24 |
Sale |
16.14 |
2,078 |
33,545 |
162,617 |
| GROENHUYSEN WILHELMUS CM | Chief Operating Officer |
Feb 28 '24 |
Sale |
16.14 |
2,303 |
37,177 |
254,559 |
1.05%
0.49%
자본화:
|
볼륨(24시간):